DNAJB6 Isoform Specific Knockdown: Therapeutic Potential for Limb Girdle Muscular Dystrophy D1.

Andrew R. Findlay,May M. Paing,Jil A. Daw,Meade Haller,Rocio Bengoechea,Sara K. Pittman,Shan Li,Feng Wang,Timothy M. Miller,Heather L. True,Tsui-Fen Chou,Conrad C. Weihl
DOI: https://doi.org/10.1016/j.omtn.2023.05.017
2023-05-18
Abstract:Dominant missense mutations in DNAJB6, a co-chaperone of HSP70, cause limb girdle muscular dystrophy (LGMD) D1. No treatments are currently available. Two isoforms exist, DNAJB6a and DNAJB6b, each with distinct localizations in muscle. Mutations reside in both isoforms, yet evidence suggests DNAJB6b is primarily responsible for disease pathogenesis. Knockdown treatment strategies involving both isoforms carry risk as DNAJB6 knockout is embryonic lethal. We therefore developed an isoform specific knockdown approach using morpholinos. Selective reduction of each isoform was achieved in-vitro in primary mouse myotubes and human LGMDD1 myoblasts, as well as in-vivo in mouse skeletal muscle. To assess isoform specific knockdown in LGMDD1, we created primary myotube cultures from a knock-in LGMDD1 mouse model. Using mass spectrometry, we identified an LGMDD1 protein signature related to protein homeostasis and myofibril structure. Selective reduction of DNAJB6b levels in LGMDD1 myotubes corrected much of the proteomic disease signature towards wild type levels. Additional in-vivo functional data is required to determine if selective reduction of DNAJB6b is a viable therapeutic target for LGMDD1.
medicine, research & experimental
What problem does this paper attempt to address?